NDAORALCAPSULE
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALTACE (ramipril) by Pfizer is animals. Approved for hypertension, heart failure, myocardial infarction and 2 more indications. First approved in 1991.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALTACE (ramipril) is an ACE inhibitor oral capsule approved in 1991 that treats hypertension, heart failure, and post-MI patients by inhibiting angiotensin-converting enzyme to reduce angiotensin II formation and vasopressor activity. The drug has broad cardio-renal protective indications including diabetic nephropathy, coronary artery disease, and ventricular dysfunction. It works by suppressing the renin-angiotensin-aldosterone system, with efficacy across racial and renin profiles.
$2MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Part D utilization signals limited growth opportunity and potential team right-sizing.
Mechanism of Action
animals. Angiotensin converting enzyme is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II,…
Indications (5)
Worked on ALTACE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.